MElkin Pharmaceuticals

Executive Summary

MElkin Pharmaceuticals is a French biotechnology company dedicated to developing innovative small molecule therapies for dermatological conditions with significant unmet medical needs. Founded in 2018 and based in Paris, the company leverages its expertise in small molecule drug discovery to address a range of skin disorders, including chronic inflammatory and autoimmune conditions. While still in the early stages of development, MElkin has built a promising pipeline of preclinical candidates targeting key pathways in dermatology. The company's focus on oral and topical small molecules offers potential advantages in patient compliance and scalability over biologic alternatives. With a lean operation and a clear strategic focus, MElkin is positioned to advance its lead programs toward clinical trials, though it remains a high-risk, early-stage investment. The absence of disclosed financials or clinical data underscores the need for further due diligence.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Dermatology Candidate40% success
• Q2 2026Completion of Preclinical Toxicology Studies60% success
• TBDPotential Partnership for a Second-Generation Molecule30% success